{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:07:46Z","timestamp":1770894466731,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1984,10,1]],"date-time":"1984-10-01T00:00:00Z","timestamp":465436800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1984,10]]},"DOI":"10.1007\/bf00269035","type":"journal-article","created":{"date-parts":[[2004,9,29]],"date-time":"2004-09-29T08:25:46Z","timestamp":1096446346000},"page":"226-229","source":"Crossref","is-referenced-by-count":1,"title":["Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer"],"prefix":"10.1007","volume":"13","author":[{"given":"Arlene A.","family":"Forastiere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann K.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"1170","volume":"42","author":"DS Alberts","year":"1982","unstructured":"Alberts DS, Mackel C, Pocelinko R, Salmon SE (1982) Phase I clinical investigation of 9,10-anthracenedicarboxaldehye-bis [(4,5-dihydro-1H-imidazol-2-yl)hydrozane] dichloride with correlative in vitro human tumor clonogenic assay. Cancer Res 42:1170","journal-title":"Cancer Res"},{"key":"CR2","unstructured":"Cavalli F, Claryse A, Bakkel Huinink WT, Clavel HM, Van Glabbeke M, Rozencweig M (1983) Phase II study of bisantrene in advanced breast cancer. Proc Am Soc Clin Oncol 2:C-441"},{"key":"CR3","unstructured":"Chang AY, Falkson G, Kaplan BH, Skeel RT, Muggia FM, Pandya KJ (1983) Phase II study of bisantrene (9,10 anthracene dicarboxaldehyde Cl 216,942) in patients with refractory breast cancer. Proc Am Soc Clin Oncol 2:C-385"},{"key":"CR4","first-page":"440","volume":"42","author":"RV Citarella","year":"1982","unstructured":"Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE, Forbes M (1982) Activity of a novel anthracenyl bishydrazone, 9,10-anthracendicarboxaldehyde-bis[(4,5-dihydro-1H-imidazol-2-yl]hydrazone) dichloride, against experimental tumors in mice. Cancer Res 42:440","journal-title":"Cancer Res"},{"key":"CR5","volume-title":"Investigators brochure: CL 216,942-9,10-anthracenedicarboxaldehyde bis-[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride","author":"Medical Research Division, American Cyanamid Co.","year":"1979","unstructured":"Medical Research Division, American Cyanamid Co. (1979) Investigators brochure: CL 216,942-9,10-anthracenedicarboxaldehyde bis-[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride. American Cyanamid, Pearl River"},{"key":"CR6","first-page":"1869","volume":"66","author":"JW Myers","year":"1982","unstructured":"Myers JW, Von Hoff DD, Coltman CA Jr, Kuhn JG, Van Echo D, Rivkin S, Pocelinko R (1982) Phase II evaluation of bisantrene (CL 216,942) in advanced renal cell carcinoma. Cancer Treat Rep 66:1869","journal-title":"Cancer Treat Rep"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00180195","volume":"1","author":"JW Myers","year":"1983","unstructured":"Myers JW, Von Hoff DD, Kuhn JG, Osborne CK, Sandbach JF, Pocelinco R (1983) Anaphylactoid reactions associated with bisantrene infusions. Investigational New Drugs 1:85","journal-title":"Investigational New Drugs"},{"key":"CR8","first-page":"357","volume":"68","author":"CK Osborne","year":"1984","unstructured":"Osborne CK, Von Hoff DD, Cowan JD, Sandbach J (1984) Bisantrene, an active drug in patients with advanced breast cancer. Cancer Treat Rep 68:357","journal-title":"Cancer Treat Rep"},{"key":"CR9","unstructured":"Sparano BM, Gordon GH, Hall C, Iatropoulos MJ, Noble TF (1980) Assessment of cardiotoxic potential of a new anticancer compound, an anthracenebishydrazone derivative in beagle dogs: comparison with Adriamycin: In: Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #31"},{"key":"CR10","first-page":"354","volume":"42","author":"RJ Spiegel","year":"1982","unstructured":"Spiegel RJ, Blum RH, Levin M, Pinto CA, Wernz JC, Speyer JL, Hoffman KS, Muggia FM (1982) Phase I clinical trial of 9,10-anthracenedicarboxaldehyde (bisantrene) administered in a five-day schedule. Cancer Res 42:354","journal-title":"Cancer Res"},{"key":"CR11","first-page":"3118","volume":"41","author":"DD Hoff Von","year":"1981","unstructured":"Von Hoff DD, Myers JW, Kuhn J, Sandbach JF, Pocelinko R, Clark G, Coltman CA (1981a) Phase I clinical investigation of 9?10 anthracenedicarboxaldehyde-bis[(4,5-dihydro-1H-imidazol-2-yl) hydrazone] dihydrochloride (CL 216,942). Cancer Res 41:3118","journal-title":"Cancer Res"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00262332","volume":"6","author":"DD Hoff Von","year":"1981","unstructured":"Von Hoff DD, Coltman CA Jr, Forseth B (1981b) Activity of 9,10-anthracenedicarboxaldehye-bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dichloride (CL 216,942) in a human tumor cloning system. Leads for phase II trials in man. Cancer Chemother Pharmacol 6:141","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR13","first-page":"1402","volume":"43","author":"H Yap","year":"1983","unstructured":"Yap H, Yap B, Blumenschein GR, Barnes BC, Schell FC, Bodey GP (1983) Bisantrene, and active new drug in the treatment of metastatic breast cancer. Cancer Res 43:1402","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00269035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00269035\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00269035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T19:21:28Z","timestamp":1554319288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00269035"}},"subtitle":["A cancer and leukemia group B study"],"short-title":[],"issued":{"date-parts":[[1984,10]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1984,10]]}},"alternative-id":["BF00269035"],"URL":"https:\/\/doi.org\/10.1007\/bf00269035","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,10]]}}}